ABOUT US
NeuroCytonix Inc., is an emerging biomedical technology company focused on developing transformational medical technologies for the regeneration of the nervous system. The company was founded in 2017 by Dr. J. Roberto Trujillo to find cures for incurable neurological diseases.
​
NeuroCytonix technology and its related protocols are a new approach to the treatment of non-progressive neurodegenerative diseases such as cerebral palsy, stroke, neurological complications of covid, and traumatic brain injury.
​
The company is headquartered in Rockville, MD near the US National Institutes of Health (NIH) at Research Boulevard within the Maryland Biotech corridor. In 2018, a clinical center was established in Monterrey, Mexico, in compliance with the FDA rules of “Good Clinical Practice” (GCP). The first FDA double-blind randomized placebo-controlled clinical trial was recently completed for cerebral palsy. The COFEPRIS and US FDA submission processes are currently in progress.
OUR CEO
J. Roberto Trujillo is a Mexican American physician, scientist, inventor, entrepreneur, and the Founder, Chairman, and CEO of NeuroCytonix, Inc., a cutting-edge translation research technology biotech focused on tissue engineering and regeneration for the cure of neurodegenerative diseases.
Meet The Team
JEFF BALAGNA
Board Member & Vice Chairman of Board
Jeff Balagna has over 35 years of experience in managing and delivering profitable growth across numerous service-related businesses in the retail, technology, medical, and hospitality industries. In addition to managing P&L for businesses and divisions exceeding $4 million in revenue, he has developed and led global teams comprising more than 10,000 employees. Jeff has extensive experience serving on Boards of Directors of public and non-profit organizations.
Over the course of his career, he has held Senior Leadership positions at many companies, including SHC, Eli Lilly, Carlson, Medtronic, GE, and Ford. Jeff’s education and professional affiliations include B.S Computer Science from Oakland University; Business Management Program from GE Crotonville, and Directors Consortium from Stanford Law.
MICHAEL BATT
Executive Vice President Marketing & Investor Relations, & Board Member
​Michael Batt is the Founder and Chairman of Internova Travel Group, a global leader providing travel services to corporate, leisure, luxury and entertainment markets. As chairman of Internova Travel Group (formerly Travel Leaders Group), Mr. Batt provides strategic direction for the company and has overseen its growth from a collection of successful travel agencies to one of the leading forces in travel today. Mr. Batt was inducted into the British Travel Industry Hall of Fame in 2014 and won the 2017 EY Entrepreneur of the Year Award for New York and was a national finalist.
ROBERT C GALLO, MD
Senior Scientific Board Advisor
Homer and Martha Gudelsky Distinguished Professor in Medicine and Co-Founder & Director, Institute Of Human Virology
​
Dr. Gallo is a world-renowned scientist who co-discovered HIV and led the team that developed the HIV blood test. His work led to therapies that have been used to prolong the lives of millions infected with the virus. Dr. Gallo was the first to identify a human retrovirus and the only known human leukemia virus. Currently he serves as director for the Institute of Human Virology.
VANDERLEI S BAGNATO, PhD
Senior Scientific Advisor
Professor, Department of Physics and Materials Science, University of São Paulo and the Institute of Physics of São Carlos, Brazil
Vanderlei Salvador Bagnato serves as a full professor at the University of São Paulo and coordinator of the USP Agency of Innovation. He has published over 250 papers in international journals with more than 4000 citations. He has been part of the editorial board of many journals and is member of Brazilian Academy of Science, The World Academy of Sciences, and The Vatican Academy of Science. He is presently the coordinator of the University of Sao Paulo Agency for Innovation.
LAURENT LAVIGNE DU CADET, MBA, PhD
CFO, COO
​Laurent Lavigne du Cadet, MBA, Finance PhD, Series 7, 24, 79, 63, 99 FINRA certified, is an experienced manager and financial expert with more than 20 years’ experience in corporate finance and M&A. Previously he served as Senior Advisor at Dentons US LLP, the largest law firm in the world. Laurent has also been the CEO and CFO of several global investment companies and has raised more than $3 billion of equity and $5 billion in debt during his career.
FERNANDO VEYTIA
Operations Director Consultant, NeuroCytonix Mexico
Fernando Veytia, has over 20 years of experience in business, financial and strategic consulting. He worked as a business strategy consultant at Accenture and Everis, as well as Director responsible for Planning at the FONACOT Institute.
During his career, he has had the opportunity to define strategies and business plans for various companies, particularly for several in the financial sector, as well as the valuation of companies and financial institutions, in addition to his experience in business operations. He also participated in the negotiations for the acceptance of the FONACOT credit card in the credit card network of the Mexican financial system, as well as in the approval of the Law of the FONACOT Institute in the H. Congress of the Union.